Inclusion Criteria:

        A subject will be eligible for study participation if he/she meets the following criteria:

          -  Subjects are eligible with B-cell malignancies, WM, FL, MCL, MZL, DLBCL, HCL, CLL,
             SLL, based upon 2016 updated WHO classification. Those subjects with WM, FL, MCL,
             DLBCL, or HCL must have received at least 2 prior systemic therapies.

          -  Low-grade B-cell lymphomas as follicular Grade 1, 2, or 3A, marginal zone or small
             lymphocytic lymphoma.

          -  Subject must have adequate coagulation, renal, and hepatic function, per local
             laboratory reference ranges at Screening as follows:

               -  Activated partial thromboplastin time (APTT) and prothrombin time (PT) not to
                  exceed 1.5 × ULN

               -  Calculated creatinine clearance (CrCl) ≥ 60 mL/min using 24-hour CrCl OR
                  Cockcroft-Gault formula.

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 1.5 ×ULN;
                  Bilirubin ≤ 1.5 × ULN (except subjects with Gilbert's Syndrome, who may have a
                  bilirubin > 1.5 × ULN, per discussion between the Investigator and the Medical
                  Monitor).

          -  Subjects must have adequate bone marrow independent of growth factor support per local
             laboratory reference range at screening as follows:

               -  Absolute Neutrophil Count (ANC) ≥1000/uL;

               -  An exception is for subjects with an ANC<1000/uL and bone marrow heavily
                  infiltrated with underlying disease (approximately 60% or more) may use growth
                  factor to achieve the ANC eligibility criteria per discussion between the
                  Investigator and the Medical Monitor.

               -  Platelet count ≥ 50,000/µL - OR - Platelet count ≥ 20,000/ µL if thrombocytopenia
                  is clearly due to CLL disease under study (per Investigator discretion)

               -  Hemoglobin ≥8.0g/dL, and can be achieved by transfusion

        Exclusion Criteria:

        A subject will not be eligible for study participation if he/she meets any of the following
        criteria.

          -  Subject has received any of the following therapies within 14 days or 5 half-lives
             (whichever is shorter) prior to the first dose of study drug, or has not recovered to
             ≤ Grade 1 clinically significant adverse effect(s)/toxicity(s) of the previous therapy
             (other than alopecia):

               -  Any anti-cancer therapy including chemotherapy, biologic or immunotherapy,
                  radiotherapy, etc;

               -  Any investigational therapy, including targeted small molecule agents.

               -  For CLL subjects who come off BCR antagonists (BTK inhibitors, PI3K inhibitors,
                  etc.) treatment, allow washout for 2 days as these subjects progress quickly
                  after treatment discontinuation and then remain eligible (steroids may be given
                  during these two days to allow disease control).

          -  Subjects who require immediate cytoreduction. However, subjects may receive up to two
             days of steroids for symptoms of impending organ impairment and remain eligible.

          -  Subject has received the following medications or therapies within 7 days prior to the
             first dose of study drug:

               -  Steroid therapy (at dosages equivalent to prednisone >20 mg/day) for
                  anti-neoplastic intent (except as noted in exclusion criteria #3);

               -  Cytochrome P450, family 3, subfamily A (CYP3A4) strong inhibitors and strong
                  CYP2C8 inducers/inhibitors.

               -  Potent CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John's
                  wort.

          -  Subjects require treatment with systemic acid-reducing agents including H-2-receptor
             antagonists and proton pump inhibitors with the following exceptions:

               -  Proton pump inhibitors should be discontinued at least 7 days prior and held
                  throughout the study

               -  If concurrent use of an H2 blocking agent is necessary, it must be administered
                  only between 2 and 3 hours after the dose of LP-168. If not taken during this
                  time, the dose of H2 blocking agents should not be taken again until 2-3 hours
                  after the next dose of LP-168.

               -  If concurrent use of a local antacid is necessary, it must be administered 2 or
                  more hours before and/or 2 or more hours after the dose of LP-168.

          -  Subject has significant screening electrocardiogram (ECG) abnormalities including. 2nd
             degree AV block type II 3rd degree block, Grade 2 or higher bradycardia, and corrected
             QT interval (QTc) ≥ 480ms.

          -  Serum amylase > 1.5 × ULN or serum lipase > 1.5 × ULN.

          -  Subject has any history of Richter's transformation for Phase 1a portion of the trial.

          -  Subjects who have undergone autologous/allogeneic hematopoietic stem cell
             transplantation (HSCT) therapy within 90 days of the first dose of LP-168, or patients
             on immunosuppressive therapy post-HSCT at the time of Screening, or currently with
             clinically significant graft-versus-host disease (GVHD) as per treating physician
             (Patients in relapse after allogeneic transplantation must be off treatment with
             systemic immunosuppressive agents for at least 4 weeks. The use of topical steroids
             and/or up to 20 mg/day prednisone or equivalent systemic steroids for ongoing GVHD is
             permitted.

          -  Subject has a history of other active malignancies other than B-cell malignancies
             within the past 3 years prior to study entry, with the exception of:

               -  Adequately treated in situ carcinoma of the cervix uteri;

               -  Basal cell carcinoma of the skin or localized squamous cell carcinoma of the
                  skin;

               -  Previous malignancy confined and surgically resected (or treated with other
                  modalities) with curative intent.

          -  Subject requires anticoagulation with Warfarin.